Suppr超能文献

评价咪唑并[2,1-b]噻唑类抗癌剂在十年间(2011-2020 年)的发展:现状与未来展望。

Evaluation of imidazo[2,1-b]thiazole-based anticancer agents in one decade (2011-2020): Current status and future prospects.

机构信息

Sharjah Institute for Medical Research, University of Sharjah, Sharjah 27272, United Arab Emirates.

Sharjah Institute for Medical Research, University of Sharjah, Sharjah 27272, United Arab Emirates; Department of Medicinal Chemistry, College of Pharmacy, University of Sharjah, Sharjah 27272, United Arab Emirates.

出版信息

Bioorg Med Chem. 2021 Jan 1;29:115897. doi: 10.1016/j.bmc.2020.115897. Epub 2020 Nov 28.

Abstract

Several reports have highlighted imidazo[2,1-b]thiazole derivatives as potential antiproliferative agents. They act through kinase inhibition, tubulin inhibition, and other molecular mechanisms of action. In the current article, we reviewed the imidazo[2,1-b]thiazole-based compounds that were reported as anticancer agents. Their biological characteristics as well as structure-activity relationship (SAR) have been reviewed and evaluated. Our main focus was on the reports published in the literature from 2011 to 2020.

摘要

已有多项报告强调咪唑并[2,1-b]噻唑衍生物具有作为潜在抗增殖剂的潜力。它们通过激酶抑制、微管蛋白抑制和其他作用机制发挥作用。在本文中,我们综述了作为抗癌剂的基于咪唑并[2,1-b]噻唑的化合物。综述并评估了它们的生物学特性和构效关系(SAR)。我们的主要关注点是 2011 年至 2020 年文献中发表的报告。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验